ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1268

Hand Bone Loss in Early Rheumatoid Arthritis Is Independent of Adalimumab Treatment – Results from a Randomized Controlled Clinical Trial. 

Lykke Midtbøll Ørnbjerg1, Mikkel Østergaard2, Trine David Jensen3, Kim Hørslev-Petersen4, Kristian Stengaard-Pedersen5, Peter Junker6, Torkell Ellingsen7, Palle Ahlquist8, Hanne Lindegaard9, Asta Linauskas10, Annette Schlemmer11, Mette Yde Dam7, Ib Hansen12, Tine Lottenburger8, Christian G. Ammitzbøll5, Anette Jørgensen5, Sophine B. Krintel1, Johnny Lillelund Raun13 and Merete Lund Hetland2, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, 3Department of Endocrinology, Hvidovre Hospital, Copenhagen, Denmark, 4King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, 5Department of Rheumatology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark, 6Department of Rheumatology C, Odense University Hospital, Odense, Denmark, 7Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark, 8Department of Medicine, Vejle Regional Hospital, Vejle, Denmark, 9The DANBIO registry and the Danish Departments of Rheumatology, Odense, Denmark, 10Department of Rheumatology, Vendsyssel Hospital, Hjørring, Denmark, 119Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 12Department of Rheumatology, Viborg Regional Hospital, Viborg, Denmark, 13King Christian X Hospital for Rheumatic Diseases, South Jutland Hospital, Graasten, Denmark

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: adalimumab and rheumatoid arthritis (RA), Digital X-ray Radiogrammetry (DXR)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Session Title: Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Rheumatoid arthritis (RA) is characterised by progressive destruction of joint bone and loss of periarticularbone mineral. Hand bone loss (HBL) measured by Digital X-ray Radiogrammetry (DXR) has been proposed as a sensitive outcome measure for treatment effect and as a potential predictor of subsequent radiographic progression in RA patients. We aimed to investigate the effect of adding adalimumab to a methotrexate and intra-articular triamcinolone treat-to-target strategy on one-year hand bone loss (HBLone-year) in early rheumatoid arthritis (RA) and to determine if HBL6months is associated with radiographic progression after two years.

Methods: In a clinical trial (OPERA) of 180 treatment-naive early RA patients (1), bone mineral density (BMD) was estimated from hand radiographs with Digital X-ray radiogrammetry (DXR) at baseline, after 6 months (n=90) and 12 months (n=70) of follow-up. Baseline and two-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL6months (0-6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (DTotal Sharp/van der Heijde Score (TSS) as dependent variable) and logistic (+/-radiographic progression (DTSS>0) as dependent variable) regression analyses. Variables with p<0.10 were included in multivariable models.

Results: In 70 patients with available HBLone-year data, HBLone-year was median (InterQuartileRange(IQR)) -1.9 (-3.3;-0.26 mg/cm2) in the placebo-group and -1.8 (-3.6;0.06) mg/cm2 in the adalimumab-group, p=0.98,Mann Whitney (Figure 1). Increased HBL (compared to general population reference values (2)) was found in 26/37 and 23/33 patients in the placebo- and adalimumab-groups, Chi-sq=0.99. In 90 patients with HBL6months data and two-year radiographic data, HBL6months was independently associated with DTSS after two years (β=-0.086 (95% Confidence Interval=-0.15;-0.025) TSS unit/mg/cm2 increase,p=0.006), and borderline associated with presence of radiographic progression (DTSS>0) (OR 0.96(0.92-1.0), p=0.10).

Conclusion: In early RA, adding adalimumab to a methotrexate-based treat-to-target strategy had no impact on HBLone-year, which was increased in both treatment groups. HBL6months was independently associated with DTSS after two years. References: 1) Hørslev-Petersen et al. Ann Rheum Dis. 2015 doi: 10.1136/annrheumdis-2015-208166. 2) Ørnbjerg LM et al. Arthritis Research & Therapy.2016, 18:53    


Disclosure: L. M. Ørnbjerg, None; M. Østergaard, None; T. D. Jensen, None; K. Hørslev-Petersen, None; K. Stengaard-Pedersen, None; P. Junker, None; T. Ellingsen, None; P. Ahlquist, None; H. Lindegaard, None; A. Linauskas, None; A. Schlemmer, None; M. Yde Dam, None; I. Hansen, None; T. Lottenburger, None; C. G. Ammitzbøll, None; A. Jørgensen, None; S. B. Krintel, None; J. L. Raun, None; M. Lund Hetland, AbbVie, BMS, MSD, Roche, Pfizer, UCB, Crescendo, 2.

To cite this abstract in AMA style:

Ørnbjerg LM, Østergaard M, Jensen TD, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Yde Dam M, Hansen I, Lottenburger T, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun JL, Lund Hetland M. Hand Bone Loss in Early Rheumatoid Arthritis Is Independent of Adalimumab Treatment – Results from a Randomized Controlled Clinical Trial.  [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/hand-bone-loss-in-early-rheumatoid-arthritis-is-independent-of-adalimumab-treatment-results-from-a-randomized-controlled-clinical-trial/. Accessed March 23, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hand-bone-loss-in-early-rheumatoid-arthritis-is-independent-of-adalimumab-treatment-results-from-a-randomized-controlled-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences